

Choosing the right SARS-CoV-2 (COVID-19) test

This guide can help you identify which COVID-19 test is right for your patients.



To determine whether a COVID-19 test for an active or current infection is needed:

- ✓ Are symptoms present?
- ✓ Has there been exposure to a known or suspected COVID-19 case?

- ✓ Are there no symptoms or have symptoms presented in the last 5 days?
- ✓ Has there been exposure to a known or suspected COVID-19 case within the last 14 days?
- ✓ Was there a previous infection and a request to leave isolation?



Consider a molecular (PCR) test

Gold standard accuracy; can be used to confirm the result of an antigen test (if needed)

This test can be used for **symptomatic patients**, those who may have been **previously exposed**, and those who may be **preparing for surgery, other medical procedures, travel, or other recreational activity**.

- Collected using a nasal swab
- Results next day (on average)

Positive SARS CoV-2 results should be treated as presumptive positive and confirmation with a molecular assay, if necessary, for patient management, may be performed.

Test Name	Test code	CPT Code
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	<u>39448</u>	87635 (HCPCS:U0003)



Consider an antigen test

Rapid results to help get “back to life” and return to travel, work, school, sports, and entertainment

This test is intended for detecting SARS-CoV-2, in individuals suspected of respiratory viral infection consistent with COVID-19 who are within 5 days of the onset of symptoms.

- Collected using a nasal swab
- Results in 15-30 minutes at point of care

Positive SARS CoV-2 results should be treated as presumptive positive and confirmation with a molecular assay, if necessary for patient management, may be performed. If patient is beyond 5 days of symptom onset, a negative SARS-CoV-2 result is possible. In symptomatic patients, a negative result should be treated as presumptive positive and confirmation with a molecular assay, if necessary, for patient management, may be performed.

Test Name	Test code
SARS-CoV-2 (COVID-19) Antigen Point-Of-Care Immunoassay for the Qualitative Detection of the SARS-CoV-2 Nucleocapsid Protein Antigen	Contact Quest

To determine if an active or current COVID-19, Flu, RSV, or other respiratory illness test is needed:

- ✓ Are symptoms present?
- ✓ Does the patient have symptoms that could overlap with other respiratory infections?



Consider a respiratory panel

Cotesting for a differential diagnosis with the convenience of a single specimen

These panels should be used for symptomatic patient diagnosis.

- Collected using a nasal swab
- Results next day (on average)

Test Name	Test code	CPT Code
NEW SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT	<u>39816</u>	0241U
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	<u>31688</u>	87636
SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	<u>31686</u>	87635 (HCPCS: U0003), 87633
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	<u>31687</u>	87635 (HCPCS: U0003), 87633, 87486, 87581

Components of panels can be ordered separately. Components available individually include Adenovirus DNA, Qualitative, Real-Time PCR (Test Code 16046); Influenza A and B Virus with Subtyping, Real-Time PCR (Test Code 91335); Parainfluenza Virus (Types 1, 2, 3 and 4) RNA, Qualitative, Real-Time PCR (Test Code 91228); Rhinovirus RNA, Real-Time PCR (Test Code 40035); Enterovirus RNA, Qualitative, Real-Time PCR (Test Code 15082); Human Metapneumovirus RNA, Qualitative, Real-Time PCR (Test Code 40034); Chlamydia pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 16003); Mycoplasma pneumoniae DNA, Qualitative, Real-Time PCR (Test Code 15498).

To determine if there is an immune response to SARS-CoV-2 (COVID-19):

Sensitivity and specificity vary by type of test used; semi-quantitative index values are not interchangeable among different manufacturers' test platforms.



Consider an antibody test

Adaptive immune response

This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

- Collected via blood draw
- Results next day (on average)
- Results are for the detection of SARS-CoV-2 antibodies. IgG and IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized

Test Name	Test code	CPT Code
SARS-CoV-2 Antibody (IgG), Spike, Semi-quantitative	<u>34499</u>	86769
SARS-CoV-2 Total Antibody, Spike, Semi-quantitative	<u>39820</u>	86769
SARS-CoV-2 Serology (COVID-19) Antibodies (IgG, IgM), Immunoassay	<u>31672</u>	86769 x2
SARS-CoV-2 Antibody (IgG), Nucleocapsid, Qualitative (a component of the IgG/IgM)	<u>39749</u>	86769

Quest powers informed decisions with access to the right COVID-19 tests

For molecular, respiratory pathogen, and antigen swab tests

Testing is available using nasal swabs, via drive-thru, or using at-home options through QuestDirect™

For antibody blood tests

You can make an appointment at any of our 2,250+ Patient Service Centers with a test order from your healthcare provider which can be purchased through QuestDirect

- The results of the semi-quantitative test should not be an indication of degree of immunity or protection from reinfection
- Positive results may occur after COVID-19 vaccination, but the clinical significance of a positive antibody result for individuals that have received a COVID-19 vaccine is unknown
- The performance of the test has not been established in COVID-19 vaccines
- The clinical significance of a negative antibody result for individuals that have received a COVID-19 vaccine is unknown

Quest is delivering the crucial insights needed to help make informed decisions during the COVID-19 pandemic. [Learn more](#) ➤

- The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests ("Tests") have not been FDA cleared or approved.
- The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorized is terminated or revoked sooner.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.
- The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Test codes may vary by location. Please contact your local laboratory for more information.

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners.
© 2021 Quest Diagnostics Incorporated. All rights reserved. MI10645 9/2021

